Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
about
Recent advances of novel targeted therapy in non-small cell lung cancerAmplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752The biology and treatment of EML4-ALK non-small cell lung cancerA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasBiological response modifiers in cancerAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsPrimary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patientsGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerIdentification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells.Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic dataRole of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancerDasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing.Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.Accelerated and increased joint damage in young mice with global inactivation of mitogen-inducible gene 6 after ligament and meniscus injury.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerMultiple roles and therapeutic implications of Akt signaling in cancer.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cellsTargeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformationsMolecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CTEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cellsN-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cellsDifferential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream EffectorsMutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingIntercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial
P2860
Q21092930-BAEC6C52-7EE3-463C-A474-FD684C9B752BQ24541450-BF675AF3-AE8A-4935-A4C8-F274F379D922Q24632625-A7873A28-93A3-441A-B7EF-484EEA593D9EQ24647928-11E90C8A-6993-4BA5-83E1-B24E67D6725AQ24648133-5D8CCFC3-BCA5-4223-9FDA-A2B0548E897BQ24669579-5C5497BF-E214-41F6-B2A5-77931FD9801BQ24685049-377FCDF9-9AF6-404D-A4A9-96D84C25AEF6Q24794765-374C9231-117C-4015-AAE3-1F0935AE943CQ24810573-9863F653-3F33-4E24-BFD9-F8A1890D4B4EQ27851396-2B37C172-39E5-4AE8-9D9A-A475E9BB7198Q27851440-01FB8AF5-C2F8-4A02-93B7-638C19E929C6Q27851633-7393D523-F587-416E-99A6-EE4CC8EB71EEQ27852993-0C76088A-541A-4510-A350-195A69489DE4Q28469345-9EE020B8-A2C1-4DDD-87C1-2B55FF505B60Q28550689-7F78821F-CD42-41D4-881E-3CFAA8839F4AQ30877356-ABCCD9D3-F3E5-49FB-BB8F-1A62EA697217Q33263277-0217F1E6-2E21-49BE-9E09-D232013CA6E4Q33401214-B01A800E-FE3C-4D8C-B7F3-A5DF85541E34Q33576845-F51BBEB9-4E9A-4282-8ECE-4B7A87010DDFQ33604480-2AFF86B0-9F19-46BF-BE11-AF3CD4BE1118Q33609045-56BD5E24-4020-4934-BC0E-DF95385CDF67Q33731181-A62474A4-B6C7-4F6E-9068-752CC2286BE4Q33765726-5EA9346C-D27B-4559-99C8-E2F5221A9390Q33821320-49D1986D-861D-4E59-AC73-82A42317B9E4Q33873095-379D2D49-C4AC-488A-92CB-457E88605801Q33915992-944F1C6E-917D-498A-965D-C6E4374A0629Q33928631-34449922-128F-4EE5-87A7-B351C530B8F4Q34060669-E2F0D343-825A-4996-8CF8-942F9AFFF8F1Q34298136-D083C0BF-36B5-494C-85C6-968C06FEB475Q34492884-59A94308-ADA7-4F17-8970-85CF38C74EF3Q34534164-32CA1F93-9334-40D3-A309-F8438A31A404Q34557318-928223AC-84C6-4394-9F23-A7D0B6FCD0D3Q34651821-75477C4B-0B3F-4419-AB83-909841A204FAQ34666826-6BAD20E0-CF55-41BD-8667-4F6E8D83A263Q34701319-514C17AB-0300-4381-8D01-EF0C7E9699ABQ35207876-398C66D1-1E45-402D-8697-24C9CCAFF2E5Q35380919-EA048AEF-114E-4CA0-839C-7BA3C3A499D9Q35434274-624E5C03-74B5-4C02-BCAA-1F1364D87A0DQ35551048-3695BD05-4118-44B0-B91C-2A3F2D382D83Q35560779-54FBB5EA-147C-47AF-AC7B-42E9D6D2328C
P2860
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
@en
type
label
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
@en
prefLabel
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
@en
P2093
P1433
P1476
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
@en
P2093
Bruce E Johnson
Mark Hansen
Sean Tracy
Toru Mukohara
P304
P356
10.1158/0008-5472.CAN-04-1905
P407
P577
2004-10-01T00:00:00Z